13:18:45 EDT Tue 27 Oct 2020
Enter Symbol
or Name

Login ID:

Shell Summary for Jan. 16, 2020

2020-01-16 21:02 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange closed up 6.10 points to 583.11 Thursday. Mohammad (Mo) Fazil's second capital pool shell, Elephant Hill Capital Inc. (EH: halted), plans to acquire two companies for its qualifying transaction: Artos Pharma Inc. and Tassili Life Sciences Corp. The shell, which has seven million shares issued, will issue 20 million shares to Artos's shareholders and between 13.75 million and 22.5 million shares to Tassili's shareholders.

Artos is a Vancouver company that is working on a treatment for advanced sarcoma (a cancer in the bone, cartilage or other types of connective tissue). Its lead drug candidate is called ART-2020. Artos has so far completed at least two phase II clinical trials for ART-2020 in Europe. The latest of those trials included 23 patients. Artos boasts that its drug candidate is doing well so far, in terms of improving survival rates as well as preventing the cancer's progression or metastasis in a patient.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2020 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.